Uniform treatment regimen for all types of leprosy patients

Uniform Multi Drug Therapy regimen for all leprosy patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/05/002696

Enrollment

3500

Registered

2012-05-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Leprosy

Interventions

Intervention1: Rifampicin, Clofazimine and Dapsone: 600 mg Rifampicin every four weeks,300 mg Clofazimine every four weeks, 50 mg clofazimine once a day, 100 mg Dapsone once a day. This 4-weeks treat

Eligibility

Inclusion criteria

Inclusion criteria: All the newly detected and treatment-naive leprosy patients will be eligible for inclusion. It is suggested the following categories of patients may be included in the study: easily accessible to the clinic, available for long-term follow-up and for receiving supervised dose of drug.

Exclusion criteria

Exclusion criteria: Newly detected pure neuritic patients, old patients, who are already receiving PB or MB-MDT, returned defaulters, and those who relapse subsequent to the earlier therapy will not be eligible for inclusion for this study.

Design outcomes

Primary

Measure	Time frame
Assess treatment response to 6 monthsâ?? Uniform MDT (UMDT) for all types of leprosy patients in terms of relapse rate not exceeding a maximum acceptable cumulative level of 8% at the end of 8 years Timepoint: Every one year post treatment	—

Secondary

Measure	Time frame
To assess acceptability, safety and compliance of UMDTTimepoint: At the end of treatment completion	—

Countries

China, India

Contacts

Public ContactDr Sanjay Mehendale

National Institute of Epidemiology

directorne@dataone.in04426136204

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026